Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Shares Outstanding (Weighted Average) (2020 - 2025)

Bolt Biotherapeutics' Shares Outstanding (Weighted Average) history spans 5 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 0.55% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, up 0.55%, while the annual FY2024 figure was $38.2 million, 0.98% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $1.9 million at Bolt Biotherapeutics, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $38.3 million in Q1 2025 and bottomed at $1.9 million in Q2 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $37.3 million (2022), against an average of $28.7 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) increased 17.18% in 2022 before it crashed 94.96% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $33.2 million in 2021, then increased by 12.54% to $37.4 million in 2022, then grew by 1.21% to $37.8 million in 2023, then grew by 0.98% to $38.2 million in 2024, then plummeted by 94.98% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Shares Outstanding (Weighted Average) are $1.9 million (Q3 2025), $1.9 million (Q2 2025), and $38.3 million (Q1 2025).